



Republic of the Philippines
Department of Health
CENTRAL OFFICE BIDS AND AWARDS COMMITTEE

COBAC RESOLUTION NO. 2018-192-B

05 November 2018

**RECOMMENDING APPROVAL FOR THE AWARD OF CONTRACT FOR THE NEGOTIATED
PROCUREMENT (TWO FAILED BIDDINGS) OF HEPATITIS B VIRAL LOAD REAGENTS
NP NO. 2018-035**

WHEREAS, Negotiated Procurement for the Hepatitis B Viral Load Reagents was conducted in accordance with the Republic Act (RA) 9184 and its 2016 Implementing Rules and Regulations (IRR) with a Total Approved Budget for the Contract (ABC) of *Thirty Seven Million Nine Hundred Ninety Two Thousand Nine Hundred Twenty Four Philippine Pesos (PhP37,992,924.00)*:

Item No.	Particular	Qty	Unit	Total ABC (PhP)
1	Hepatitis B Viral Load Reagents	400	Set	37,992,924.00

WHEREAS, the COBAC Resolution No. 2018-192 "Declaration of Failure of Bidding for the Procurement of Hepatitis B Viral Load Reagents", was approved;

WHEREAS, the COBAC Resolution No. 2018-192-A "Declaration Of Second Failure Of Bidding and Recommending Approval on the Use of Negotiated Procurement (Two Failed Biddings) for the Procurement of Hepatitis B Viral Load Reagents – Re-Bid", was approved;

WHEREAS, on 24 August 2018, a Pre-procurement Conference and Mandatory Review was conducted at 10:30 AM at the COBAC Conference Room, Department of Health (DOH) to discuss the details of the procurement at hand;

WHEREAS, on the same date 2018, a memorandum was issued to Disease Prevention and Control Bureau (DPCB) relative to the changes made in the said conference;

WHEREAS, on 30 August 2018, DPCB submitted a revised Purchase Request (PR);

WHEREAS, on 13 September 2018, the Request for Best and Final Offer (RBFO) was posted in the PhilGEPS website and other conspicuous places within the premises of the DOH;

WHEREAS, the RBFO was sent to three (3) prospective bidders listed below:

- 1) Lifeline Diagnostics Supplies Inc. (LDSI);
- 2) Metro Drug Inc. (MDI) and;
- 3) Macare Medicals Inc. (MMI);

WHEREAS, the Technical Working Group (TWG) was created through the issuance of Department Personnel Order (DPO) COBAC No. 2018-385 dated 18 September 2018;

WHEREAS, the Submission and Opening of Bids took place as scheduled on 18 September 2018 9:00 A.M. at the COBAC Conference Room, DOH;

WHEREAS, one (1) prospective bidder submitted its proposal, namely, MDI JV with Interpharma Holdings and Management Corporation (IHMC);

WHEREAS, the envelope containing the Eligibility and Technical Documents were opened and the presence, completeness and correctness of all documents were verified by the COBAC-C;

WHEREAS, upon examination, MDI JV with IHMC was declared "ELIGIBLE" and was rated "PASSED" and subsequently its proposal was read and posted in the Abstract of Bids, to wit:

Name of Company				MDI JV with IHMC
REMARKS				ELIGIBLE/PASSED
Item No.	Item Description	Qty/Unit	TOTAL ABC (PhP)	BID PRICE AS READ (PhP)
1	<i>Hepatitis B Viral Load Reagents</i>	400 sets	37,992,924.00	36,000,000.00

WHEREAS, MDI JV with IHMC was declared the Single Bidder subject to further review and correction of the financial bid;

WHEREAS, the bid for the item listed below was found to be substantially complying:

400 sets – Hepatitis B Viral Load Reagents

Bidder No.	Name of Company	ABC (PhP)	Bid as Calculated Amount (PhP)	% Variance from ABC
1	MDI JV with IHMC	37,992,924.00	36,000,000.00	5.24%

WHEREAS, on 19 September 2018, the detailed evaluation of the submitted documents of MDI JV with IHMC was undertaken by the designated TWG;

WHEREAS, on 27 September 2018, the TWG submitted its consolidated evaluation report for MDI JV with IHMC citing their bid as "complying";

WHEREAS, on 28 September 2018, the cited report was presented to COBAC-C during its 40th Regular Meeting. Upon review, the Committee concurred with the TWG and decided to proceed with the post-qualification process upon receipt of the additional documentary requirements;

WHEREAS, on 02 October 2018, a notice was issued through facsimile and electronic mail (e-mail) to the MDI JV with IHMC requesting for the submission of additional Post-Qualification requirements;

WHEREAS, on 08 October 2018, MDI JV with IHMC submitted the additional post-qualification requirements and was subsequently forwarded to the TWG for further evaluation;

WHEREAS, on 20 October 2018, the TWG found MDI JV with IHMC's proposal responsive;

WHEREAS, on 30 October 2018, the above-cited TWG report was presented to the COBAC-C during its 43rd Meeting. The committee concurred with the TWG's report and recommended the award of contract to MDI JV with IHMC;

WHEREAS, at the time of the signing of this resolution, there is no pending incident, no pending Request for Reconsideration, no pending Protest and the COBAC-C followed the requirements set forth in R.A. 9184;

NOW THEREFORE, on the basis of the above, the **Metro Drug Inc. JV with Interpharma Holdings and Management Corporation** as determined to be the Single Calculated Responsive Bid (SCRB) with a Total Contract Price of **Thirty Six Million Philippine Pesos (PhP36,000,000.00)** inclusive of local taxes for the procurement of the item listed below:

Item No.	Particular	Qty	Unit	Total Bid Price (PhP)
1	Hepatitis B Viral Load Reagents	400	Set	36,000,000.00

DEC 10 2018

Signed this ____ day of ____ 2018 at the Department of Health, San Lazaro Compound, Sta. Cruz, Manila.

CENTRAL OFFICE BIDS AND AWARDS COMMITTEE (COBAC) – C

GLORIA J. BALBOA, MD, MPH, CEO VI, CESO III
Regular Member

OUTSIDE MEETING
DAVID P. MASIADO, JR., ME, MM
Regular Member

LAUREANO C. CRUZ, MPA
Regular Member

JOSELITO R. FELICIANO, MD
Vice-Chairperson

OUTSIDE MEETING
LYNDON L. LEE SUY, MD, MPH
Assistant Secretary of Health
COBAC – C Chairperson

By Authority of the Secretary of Health:

DEC 28 2018

MARIA ROSARIO S. VERGEIRE, MD, MPH, CESO IV
Assistant Secretary of Health
Public Health Services Team